Hostname: page-component-7479d7b7d-qlrfm Total loading time: 0 Render date: 2024-07-09T01:31:29.006Z Has data issue: false hasContentIssue false

The rationale, design, and progress of two novel maintenance treatment studies in pediatric bipolarity

Published online by Cambridge University Press:  18 September 2015

R.L. Findling*
Affiliation:
Departments of Psychiatry and Pediatrics, Case Western Reserve UniversityUniversity Hospitals of Cleveland, USA
B.L. Gracious
Affiliation:
Departments of Psychiatry and Pediatrics, Case Western Reserve UniversityUniversity Hospitals of Cleveland, USA
N.K. McNamara
Affiliation:
Departments of Psychiatry and Pediatrics, Case Western Reserve UniversityUniversity Hospitals of Cleveland, USA
J.R. Calabrese
Affiliation:
Departments of Psychiatry and Pediatrics, Case Western Reserve UniversityUniversity Hospitals of Cleveland, USA
*
Child & Adolescent Psychiatry, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio 44106-5080, USA, Tel 216-8443881, Fax 216-8445883

Abstract

Introduction: There are no definitively established acute or maintenance treatments for juvenile bipolar disorder.

Method: Two randomized, blind, maintenance clinical trials in children and adolescents with bipolar disorders are ongoing at the University Hospitals of Cleveland/Case Western Reserve University Stanley Clinical Research Center for bipolar disorder. The first is comparing the safety and effectiveness of lithium carbonate (Li+) to divalproex sodium (VPA) for up to 76 weeks in youths with stabilized bipolar illness (type 1 or 2). The second study is designed to compare the efficacy of VPA to placebo in the acute management of subsyndromal symptoms of bipolar disorder (‘cyclotaxia’) and the prevention of the full syndrome in children at risk. Both studies use the prospective life-chart method as an outcome measure.

Results: Sixty-six youths have received study medication as part of the trial that is comparing Li+ to VPA as a maintenance therapy. In addition, 32 youths have received blinded treatment as part of the ‘cyclotaxia’ prevention study. Combination Li+A/PA treatment appears generally well tolerated and seems to have robust anti-manic and antidepressant effects.

Discussion: Since the blind has not been broken on either of these clinical trials, conclusions about the maintenance effectiveness of either VPA or Li+ in youths with bipolar disorder type 1 or 2 cannot be made yet. Similarly, it is unclear whether VPA is superior to placebo in genetically high-risk youths with cyclotaxia. The final results of these trials should provide valuable information about the treatment of juvenile bipolar disorders.

Type
Articles
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Schou, M. Forty years of lithium treatment. Arch Gen Psychiatry 1997;54:913.CrossRefGoogle ScholarPubMed
2.Kowatch, RA, Bucci, J P. Mood stabilizers and anticonvulsants. Ped Clin North America 1998;45:11731186.CrossRefGoogle ScholarPubMed
3.Davanzo, PA, McCracken, JT. Mood stabilizers in the treatment of juvenile bipolar disorder. Child Adolesc Psychiatr Clin North America 2000;9:159182.CrossRefGoogle ScholarPubMed
4.Geller, B, Cooper, TB. Sun, K. Zimerman, B, Frazier, J. Williams, M. Heath J. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37:171178.CrossRefGoogle ScholarPubMed
5.Strober, M, Morrell, W, Lampert, C, Burroughs, J. Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar 1 illness: a naturalistic study. Am J Psychiatry 1990;147:457461.Google Scholar
6.Post, RM. Weiss, SRB, Leverich, GS, George, MS. Frye, M, Ketter, TA. Developmental psychobiology of cyclic affective illness: implications for early therapeutic intervention. Developm Psychopathol 1996;8:273305.CrossRefGoogle Scholar
7.Calabrese, JR, Woyshville, MJ. A medication algorithm for treatment of bipolar rapid cycling. J Clin Psychiatry 1995;56[suppl 3]: 1118.Google ScholarPubMed
8.Jacobsen, FM. Low-dose divalproex sodium: a new treatment for cyclothymia, mild rapid cycling disorder, and premenstrual syndrome. J Clin Psychiatry 1993;54:229234.Google ScholarPubMed
9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington. DC. American Psychiatric Association, 1994.Google Scholar
10.Poznanski, EO, Freeman, LN, Mokros, HB. Children's Depression Rating Scale-Revised. Psychopharmacol Bull 1985;21:979989.Google Scholar
11.Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429435.CrossRefGoogle ScholarPubMed
12.Shaffer, D, Gould, MS, Brasie, J, Ambrosini, P, Fisher, P, Bird, H, Aluwahlia, S. A children's global assessment scale (CGAS) for children 4 to 16 years of age. Psychopharmacol Bull 1985;21:747748.Google Scholar
13.Roy-Byrne, P, Post, RM, Uhde, TW, Porcu, T, Davis, D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatrica Scand Suppl 1985;317:534.Google ScholarPubMed
14.Denicoff, KD, Smith-Jackson, EE, Disney, ER, Suddath, RL, Leverich, GS, Post, RM. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Psychiatr Res 1997;31:593603.CrossRefGoogle ScholarPubMed